Exagen Inc. (NASDAQ:XGN) has earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $26.00.
Several analysts recently issued reports on XGN shares. Zacks Investment Research raised Exagen from a “sell” rating to a “hold” rating in a research note on Wednesday, July 14th. BTIG Research cut their target price on Exagen from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, August 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Exagen in a research report on Friday, July 9th.
In other news, Director James L. L Tullis sold 10,858 shares of the business’s stock in a transaction that occurred on Monday, June 28th. The stock was sold at an average price of $14.98, for a total value of $162,652.84. Following the sale, the director now directly owns 21,348 shares of the company’s stock, valued at approximately $319,793.04. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 14,758 shares of company stock worth $208,028. Insiders own 48.90% of the company’s stock.
XGN opened at $13.65 on Wednesday. The company has a market cap of $220.13 million, a P/E ratio of -9.29 and a beta of 0.54. The business’s 50-day moving average price is $13.06 and its 200-day moving average price is $14.93. The company has a current ratio of 15.07, a quick ratio of 15.07 and a debt-to-equity ratio of 0.28. Exagen has a 12 month low of $10.13 and a 12 month high of $24.67.
Exagen (NASDAQ:XGN) last posted its earnings results on Monday, August 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.12. Exagen had a negative return on equity of 28.69% and a negative net margin of 43.54%. Equities research analysts forecast that Exagen will post -1.68 earnings per share for the current fiscal year.
Exagen Company Profile
Exagen Inc develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Recommended Story: Conference Calls and Individual Investors
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.